<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Temozolomide (TMZ) is a widely used oral <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> that has been associated with the development of severe hematologic adverse events (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAEs</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Limited clinical information about <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAEs</z:e> is available </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We searched the FDA MedWatch database for TMZ and obtained <z:hpo ids='HP_0000001'>all</z:hpo> MedWatch reports on TMZ submitted to the FDA from November 1, 1997 to September 3, 2008 </plain></SENT>
<SENT sid="3" pm="."><plain>We defined major <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAEs</z:e>, namely <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, <z:mpath ids='MPATH_58'>aplasia</z:mpath>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA), <z:hpo ids='HP_0001909'>leukemia</z:hpo> (various), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and several minor <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAEs</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 5,127 reports on 3,490 patients were submitted to MedWatch </plain></SENT>
<SENT sid="5" pm="."><plain>Among these, we identified 112 cases of major <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAEs</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 44 reported <z:hpo ids='HP_0011420'>deaths</z:hpo>, the major <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAE</z:e> was considered the cause in 32 cases </plain></SENT>
<SENT sid="7" pm="."><plain>The median duration of TMZ treatment was 6 weeks [0.5-108 weeks] </plain></SENT>
<SENT sid="8" pm="."><plain>Seventy-six cases of AA or <z:mpath ids='MPATH_58'>aplasia</z:mpath> and 17 cases of <z:hpo ids='HP_0001909'>leukemia</z:hpo> represented the most common major <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAE</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Important minor <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAEs</z:e> were <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> and <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>/<z:hpo ids='HP_0001876'>pancytopenia</z:hpo>-like with 325 combined cases; these reports are clinically similar to <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The hematologic toxicity profile of TMZ differs from that of other <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>TMZ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HAEs</z:e> are emerging as significant concerns </plain></SENT>
<SENT sid="12" pm="."><plain>Among <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, AA appears unique to TMZ, and the high rate warrants disclosure of patients </plain></SENT>
<SENT sid="13" pm="."><plain>The duration of TMZ exposure prior to the development of AA may be quite short </plain></SENT>
<SENT sid="14" pm="."><plain>The risk of <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> is low, but the length of follow-up is insufficient to assess the true risk </plain></SENT>
</text></document>